- Home
- IMMX vs JBGS Comparison
IMMX vs JBGS Comparison
Compare IMMX & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMX | JBGS |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.2M | 823.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMMX | JBGS |
|---|---|---|
| Price | $11.34 | $11.39 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $19.20 | $15.00 |
| AVG Volume (30 Days) | ★ 1.7M | 799.5K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $498,598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.94 | $10.77 |
| 52 Week High | $12.14 | $24.30 |
Technical Indicators
Market Signals| Indicator | IMMX | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 28.88 |
| Support Level | $7.96 | $10.77 |
| Resistance Level | $11.87 | $15.27 |
| Average True Range (ATR) | 0.73 | 0.55 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 88.99 | 17.42 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.